Studies have confirmed: long -term small doses of aspirin may shorten the new crown disease
Recently, the joint prevention and control mechanism of the State Council issued the “Notice on Printing and Distributing the Guide to the Home Treatment of the New Crown Virus infection” (referred to as the “Guide”), and provided a common drug reference table for the new crown virus infected in the “Guide”.Among them, in the choice of antipyretic drugs, in addition to the attractive ibuprofen and acetaminol, aspirin also appeared.
(Picture source: “Notice on the Guide to Printing and Distributing the Treatment of Home Treatment of New Crown Viruses”)
Aspirin (ASpirin, acetyl acid) has more than a century of clinical application history since its launch in 1898.When used for colds and fever, you should choose a large dose of 300-500mg. It is a non-prescription medicine. It is usually a pouring tablet for easy to take and quickly take effect.
The aspirin enteric -soluble tablets are prescribed drugs. It is 100mg of small doses once a day. It is used for cardiovascular and cerebrovascular disease prevention and needs to be used under the guidance of professional medical people.In cardiovascular disease prevention, if the patient does not take aspirin’s contraindications or serious adverse reactions, he should adhere to long -term or even lifelong prevention medicine.If you are discontinued or irregular, you may induce thrombosis, thereby increasing the risk of cardiovascular adverse incidents.
It is worth mentioning that in the context of the global new crown virus popularity, there are continuous studies that long -term small doses of aspirin may have a positive impact on the new crown sensuality, course, and even mortality.
A study of Israel queues shows that the use of aspirin as a first-level prevention and COVID-19 test results are less correlated. Even if infection, the course of the disease is about 1.2 times than the unused population, and it can even improve the patients with new crown patients.Survival rate.
Researchers from the British Empire Institute of Technology and the University of Bristeo published a random clinical trial paper in the American Medical Association Magazine (JAMA), involving France, Germany, the United Kingdom, Canada, Italy and other countries from 2020 to 2021.1557 of the 105 hospitals of the hospital.Some of them took aspirin, and some were taken at clopidogre, and the remaining patients did not take any antiplatelet drugs.According to the experimental results, new coronary patients treated with anti -platelet drugs such as aspirin, although they did not change their demand for life support systems such as ventilator in the short term, it will improve their survival rate in the next three months.
Researchers at the School of Medicine at the University of Malays in the United States also found that among the patients who are hospitalized for COVID-19, those patients who take small doses of aspirin daily for cardiovascular disease to prevent cardiovascular disease have a probability of complications and death in complications compared to unused patients.Risk is significantly reduced.
Although the new crown strains have been weakened after many iterations and mutations, the pathogenicity has been greatly weakened, but it is still a threat that cannot be underestimated for patients with cardiovascular and cerebrovascular diseases.
references:
, Doi: 10.1111/Febs.15784
-1259., Doi: 10.1001/JAMA.2022.2910
